Published in J Biol Chem on December 23, 2006
Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis. Cancer Cell (2015) 2.21
Transcriptional diversity during monocyte to macrophage differentiation. Immunol Lett (2008) 1.06
25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab (2008) 1.04
Reduction in dietary omega-6 polyunsaturated fatty acids: eicosapentaenoic acid plus docosahexaenoic acid ratio minimizes atherosclerotic lesion formation and inflammatory response in the LDL receptor null mouse. Atherosclerosis (2008) 1.03
Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J Pharmacol Exp Ther (2008) 0.99
Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis. J Biol Chem (2010) 0.99
Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem (2010) 0.99
Nascent HDL formation in hepatocytes and role of ABCA1, ABCG1, and SR-BI. J Lipid Res (2011) 0.97
Nobiletin attenuates VLDL overproduction, dyslipidemia, and atherosclerosis in mice with diet-induced insulin resistance. Diabetes (2011) 0.94
Oxysterols and their cellular effectors. Biomolecules (2012) 0.92
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. J Lipid Res (2014) 0.88
Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation. Am J Physiol Endocrinol Metab (2013) 0.87
LXR agonist increases apoE secretion from HepG2 spheroid, together with an increased production of VLDL and apoE-rich large HDL. Lipids Health Dis (2011) 0.86
Suppression of 2,3-oxidosqualene cyclase by high fat diet contributes to liver X receptor-alpha-mediated improvement of hepatic lipid profile. J Biol Chem (2009) 0.83
Mulberry leaves (Morus alba L.) ameliorate obesity-induced hepatic lipogenesis, fibrosis, and oxidative stress in high-fat diet-fed mice. Genes Nutr (2015) 0.81
The oxysterol 24(s),25-epoxycholesterol attenuates human smooth muscle-derived foam cell formation via reduced low-density lipoprotein uptake and enhanced cholesterol efflux. J Am Heart Assoc (2012) 0.80
Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage. J Neuroinflammation (2016) 0.79
Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol (2013) 0.79
Enhanced aortic macrophage lipid accumulation and inflammatory response in LDL receptor null mice fed an atherogenic diet. Lipids (2010) 0.77
Practical strategies for modulating foam cell formation and behavior. World J Clin Cases (2014) 0.76
Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism, Carbohydrate Metabolism, and Innate Immunity. Curr Signal Transduct Ther (2008) 0.76
Bis(monoacylglycero)phosphate accumulation in macrophages induces intracellular cholesterol redistribution, attenuates liver-X receptor/ATP-Binding cassette transporter A1/ATP-binding cassette transporter G1 pathway, and impairs cholesterol efflux. Arterioscler Thromb Vasc Biol (2013) 0.75
The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Horm Cancer (2016) 0.75
Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages. PLoS One (2016) 0.75
Liver X Receptors as Therapeutic Targets for Managing Cholesterol: Implications for Atherosclerosis and Other Inflammatory Conditions. Clin Lipidol (2009) 0.75
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Hypertriglyceridemia: its etiology, effects and treatment. CMAJ (2007) 3.42
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Narrative review: statin-related myopathy. Ann Intern Med (2009) 2.36
N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med (2014) 2.28
Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice. Gastroenterology (2009) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Kinase mutations in human disease: interpreting genotype-phenotype relationships. Nat Rev Genet (2010) 2.14
SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol (2002) 2.12
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest (2009) 1.83
Alstrom syndrome (OMIM 203800): a case report and literature review. Orphanet J Rare Dis (2007) 1.79
Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. Circ Cardiovasc Genet (2011) 1.78
Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet (2008) 1.77
Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov (2008) 1.74
Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis (2007) 1.72
The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. Nat Med (2011) 1.70
TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. Am J Hum Genet (2011) 1.65
Genetic determinants of plasma triglycerides. J Lipid Res (2010) 1.63
Congenital and acquired long QT syndromes. Can J Cardiol (2003) 1.59
Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues. Can J Cardiol (2008) 1.59
Lipid incorporation inhibits Src-dependent assembly of fibronectin and type I collagen by vascular smooth muscle cells. Circ Res (2009) 1.56
Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med (2006) 1.55
APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med (2008) 1.52
Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. Nephrol Dial Transplant (2007) 1.49
A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet (2009) 1.49
Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol (2013) 1.47
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. Can J Cardiol (2012) 1.47
Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol (2007) 1.46
Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors. Diabetes Care (2005) 1.46
Complex trait locus linkage mapping in atherosclerosis: time to take a step back before moving forward? Arterioscler Thromb Vasc Biol (2005) 1.46
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids Health Dis (2008) 1.41
LMNA is mutated in Hutchinson-Gilford progeria (MIM 176670) but not in Wiedemann-Rautenstrauch progeroid syndrome (MIM 264090). J Hum Genet (2003) 1.40
Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin. Can J Cardiol (2013) 1.39
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes (2009) 1.36
The heritability of mammographically dense and nondense breast tissue. Cancer Epidemiol Biomarkers Prev (2006) 1.35
Extremes of unexplained variation as a phenotype: an efficient approach for genome-wide association studies of cardiovascular disease. Circ Cardiovasc Genet (2010) 1.33
Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. Circ Cardiovasc Genet (2009) 1.30
Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke (2010) 1.30
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ (2006) 1.30
Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis. Arch Neurol (2009) 1.30
Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum Genet (2003) 1.29
Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation (2009) 1.26
Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke (2004) 1.26
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Exome sequencing as a diagnostic tool for pediatric-onset ataxia. Hum Mutat (2014) 1.25
Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample. Cardiovasc Diabetol (2008) 1.23
DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet (2002) 1.22
Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis (2008) 1.20
Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem (2005) 1.19
Metabolic syndrome and its components as predictors of incident type 2 diabetes mellitus in an Aboriginal community. CMAJ (2009) 1.19
Meta-analysis of the INSIG2 association with obesity including 74,345 individuals: does heterogeneity of estimates relate to study design? PLoS Genet (2009) 1.18
Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab (2007) 1.16
Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can J Physiol Pharmacol (2009) 1.15
Genetic determinants of statin intolerance. Lipids Health Dis (2007) 1.15
Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care (2008) 1.14
HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis (2007) 1.14
Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. J Lipid Res (2009) 1.14
Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis (2005) 1.13
Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke (2004) 1.13
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res (2006) 1.12
Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol (2011) 1.12
Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of ApoB and ApoB-containing lipoproteins in familial hypobetalipoproteinemia. J Biol Chem (2007) 1.12
Gene-gene and gene-environment interactions: new insights into the prevention, detection and management of coronary artery disease. Genome Med (2009) 1.12
Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling. Am J Hum Genet (2010) 1.11
Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. Atherosclerosis (2006) 1.11
Phenomics: expanding the role of clinical evaluation in genomic studies. J Investig Med (2010) 1.10
Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol (2011) 1.10
Low incidence of cardiovascular disease among the Inuit--what is the evidence? Atherosclerosis (2003) 1.09